Trump signs executive order easing U.S. restrictions on psychedelic research
perigon
Last updated: April 19, 2026
President Trump signed an executive order Saturday that eases restrictions on research into psychedelics, specifically mentioning ibogaine. This drug is currently used in some countries for treating post-traumatic stress disorder (PTSD). The executive order signals a potential shift in the U.S. approach to studying these substances.
- The executive order aims to facilitate further scientific investigation into the therapeutic potential of psychedelic compounds. Ibogaine, derived from the West African iboga plant, has shown promise in clinical settings for treating addiction and PTSD.
- By reducing existing regulatory barriers, the order intends to encourage more comprehensive studies on the efficacy and safety of these substances. This could lead to a better understanding of their medicinal applications and potential benefits for patients suffering from various mental health conditions.
- The move may also stimulate investment and innovation in the field of psychedelic-assisted therapy. It represents a step towards exploring alternative treatment modalities for conditions where conventional therapies have proven insufficient.
